These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 22721364)
1. [Epidemiology and clinical assessment of spasticity in multiple sclerosis]. Bensmail D; Vermersch P Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S45-50. PubMed ID: 22721364 [TBL] [Abstract][Full Text] [Related]
2. [Spasticity and everyday life in multiple sclerosis]. Donzé C; De Sèze J Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S51-6. PubMed ID: 22721365 [TBL] [Abstract][Full Text] [Related]
3. [Non-medicinal treatments of spasticity in multiple sclerosis]. Mailhan L; Papeix C Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S57-61. PubMed ID: 22721366 [TBL] [Abstract][Full Text] [Related]
4. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. Anwar K; Barnes MP NeuroRehabilitation; 2009; 24(4):333-40. PubMed ID: 19597271 [TBL] [Abstract][Full Text] [Related]
6. Spasticity in multiple sclerosis: results of a patient survey. Oreja-Guevara C; González-Segura D; Vila C Int J Neurosci; 2013 Jun; 123(6):400-8. PubMed ID: 23297730 [TBL] [Abstract][Full Text] [Related]
7. A randomized trial of memantine as treatment for spasticity in multiple sclerosis. Mehta LR; McDermott MP; Goodman AD; Schwid SR Mult Scler; 2010 Feb; 16(2):248-51. PubMed ID: 20028712 [TBL] [Abstract][Full Text] [Related]
8. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Pozzilli C Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844 [TBL] [Abstract][Full Text] [Related]
9. [Spasticity in multiple sclerosis]. Pappalardo A; Patti F; Reggio A; Guglielmino A; Mangiameli S Clin Ter; 2004 Apr; 155(4):135-8. PubMed ID: 15354762 [TBL] [Abstract][Full Text] [Related]
11. Levetiracetam for phasic spasticity in multiple sclerosis. Hawker K; Frohman E; Racke M Arch Neurol; 2003 Dec; 60(12):1772-4. PubMed ID: 14676055 [TBL] [Abstract][Full Text] [Related]
12. Functional outcome of intrathecal baclofen administration for severe spasticity. Boviatsis EJ; Kouyialis AT; Korfias S; Sakas DE Clin Neurol Neurosurg; 2005 Jun; 107(4):289-95. PubMed ID: 15885386 [TBL] [Abstract][Full Text] [Related]
13. Toward an epidemiology of poststroke spasticity. Wissel J; Manack A; Brainin M Neurology; 2013 Jan; 80(3 Suppl 2):S13-9. PubMed ID: 23319481 [TBL] [Abstract][Full Text] [Related]
14. Effect of spasticity on kinematics of gait and muscular activation in people with Multiple Sclerosis. Pau M; Coghe G; Corona F; Marrosu MG; Cocco E J Neurol Sci; 2015 Nov; 358(1-2):339-44. PubMed ID: 26409825 [TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Oreja-Guevara C Expert Rev Neurother; 2012 Apr; 12(4 Suppl):3-8. PubMed ID: 22509985 [TBL] [Abstract][Full Text] [Related]
16. Effect of a 4-week period of unloaded leg cycling exercise on spasticity in multiple sclerosis. Sosnoff J; Motl RW; Snook EM; Wynn D NeuroRehabilitation; 2009; 24(4):327-31. PubMed ID: 19597270 [TBL] [Abstract][Full Text] [Related]
20. Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity. Arroyo R; Vila C; Dechant KL J Comp Eff Res; 2014 Jul; 3(4):435-44. PubMed ID: 25275238 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]